Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients

Transplant International

Volumn 24, Issue 3, 2011, Pages 276-283

  Kovarik, John M ^a   Neuhaus, Peter ^b   Cillo, Umberto ^c   Weber, Markus ^d   Stitah, Sylvie ^a   Gatlik, Ewa ^a   Meiser, Karin ^a   Slade, Alan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

immunosuppression; liver transplantation; pharmacokinetics; protein kinase C

Indexed keywords

OROSOMUCOID; PROTEIN KINASE C INHIBITOR; SOTRASTAURIN; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

EID: 79551545338     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01196.x     Document Type: Article

References (14)

1. Weckbecker G, Pally C, Beerli C, et al. Effects of the novel protein kinase C inhibitor AEB071 (sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. Transpl Int 2010; 23: 543.
2. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a small molecule inhibiting protein kinase C: first clinical results in renal transplant recipients. Am J Transplant 2010; 10: 571.
3. Skvara H, Dawid M, Kleyn E, et al. Potential therapeutic option for psoriasis with AEB071, a novel protein kinase C inhibitor. J Clin Invest 2008; 118: 3151.
4. Soltes L,. The Hummel-Dreyer method: impact in pharmacology. Biomed Chromatogr 2004; 18: 259.
5. Banker MJ, Clark TH, Williams JA,. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 2003; 92: 967.
6. Slade A, Vitaliti A, Agyemang A, Sieberling M, Schmouder R,. AEB071: human pharmacodynamics in combination with mycophenolic acid [Abstract]. Transplantation 2006; 82 (Suppl. 3): 199.
7. Mueller EA, Kallay Z, Kovarik JM, et al. Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. Transplantation 1995; 60: 515.
8. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ,. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit 2004; 26: 506.
9. Bullingham RES, Nicholls AJ, Kamm BR,. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429.
10. Huang ML, Venkataramanan R, Burckhart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE,. Drug-binding proteins in liver transplant patients. J Clin Pharmacol 1988; 28: 505.
11. Kovarik JM, Stitah S, Slade A, et al. Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses. J Clin Pharmacol 2010; 50: 1260.
12. Kovarik JM, Steiger JU, Grinyo JM, et al. Tacrolimus pharmacokinetics when combined with the protein kinase C inhibitor AEB071 in de novo kidney transplant patients [Abstract]. Am J Transplant 2009; 9 (Suppl. 2): 323.
13. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 1211.
14. Ku YM, Min DI,. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit 1998; 20: 219.